Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $230 from $220 on January 12, preserving a Buy rating on the company. The rise follows practice-changing results from the HERIZON-GEA trial, which Truist used to justify adjusting its Ziihera estimations higher. In order to get a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy with priority review, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) executives intends to file a supplemental Biologics License Application (sBLA) in the initial half of 2026. After clearance based on clinical data, Truist Securities anticipates strong commercial adoption, probable adoption in NCCN guidelines, over 90% prescriber crossover between GEA and biliary tract cancer (BTC), and compatibility of PD-1 inhibitor selection. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelc
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Is Jazz Pharmaceuticals (JAZZ) Offering An Opportunity After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.MarketBeat
JAZZ
Earnings
- 11/5/25 - Beat
JAZZ
Sec Filings
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- JAZZ's page on the SEC website